Android Apple

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

By Yahoo! Finance   |   2 months ago
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

A study found that the sa-mRNA COVID-19 vaccine is more effective than Comirnaty against various variants at one-sixth the dose. The sa-mRNA vaccine Kostaive is approved in Japan. ARCT-2301 also shows superior immunogenicity over Comirnaty.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.